Management of Statin-Intolerant Patients with Fenofibrate

Introduction to Fenofibrate as a Statin Alternative

The American College of Cardiology recommends fenofibrate as an appropriate alternative lipid-lowering agent for patients with documented statin allergy or intolerance, due to its distinct drug class with no cross-reactivity to statins 1, 2

Fenofibrate should be considered in patients with hypertriglyceridemia (triglycerides >150 mg/dL) who cannot tolerate any statin formulation, according to the American College of Cardiology and Diabetes Care 1, 3
The American College of Cardiology and American Journal of Kidney Diseases suggest that fenofibrate is necessary for immediate treatment in cases of severe hypertriglyceridemia (triglycerides ≥500 mg/dL) to prevent acute pancreatitis, regardless of statin tolerance 1, 4
Diabetes Care recommends fenofibrate for patients with low HDL-C (<40 mg/dL in men, <50 mg/dL in women) as the primary lipid abnormality in statin-intolerant patients 3

The American College of Cardiology states that fenofibrate is contraindicated in patients with moderate to severe renal impairment (eGFR <30 mL/min/1.73 m²) 1
The American College of Cardiology recommends dose reduction to a maximum of 54 mg/day if eGFR is 30-59 mL/min/1.73 m² 1
The American College of Cardiology and American Journal of Kidney Diseases suggest monitoring renal function within 3 months of initiation, then every 6 months thereafter, and discontinuing fenofibrate if eGFR persistently drops to <30 mL/min/1.73 m² 1, 4
The American College of Cardiology recommends obtaining baseline hepatic transaminases before starting fenofibrate, as liver enzyme elevations can occur 1

Diabetes Care advises against assuming the patient needs statin therapy if fenofibrate addresses their primary lipid abnormality—if hypertriglyceridemia or low HDL-C is the dominant issue and LDL-C is at goal, fenofibrate monotherapy may be sufficient 3
The American College of Cardiology and Diabetes Care recommend never delaying fenofibrate initiation in severe hypertriglyceridemia (≥500 mg/dL) while attempting statin rechallenge, as pancreatitis risk is immediate 1, 3
The American College of Cardiology suggests avoiding the use of fenofibrate in patients with active liver disease or unexplained persistent transaminase elevations, as this represents a contraindication 1

The American College of Cardiology recommends taking fenofibrate ≥2 hours before or ≥4 hours after bile acid sequestrants to avoid binding interactions that reduce fenofibrate absorption 2